SERCA INHIBITOR AND CALMODULIN ANTAGONIST COMBINATION
申请人:UNIVERSITAET DES SAARLANDES
公开号:US20160067261A1
公开(公告)日:2016-03-10
The present invention relates to novel combinations of active ingredients for use in the prevention and/or treatment of tumors. The tumors treated by the composition according to the invention overexpress SEC62 gene and overproduce Sec62 protein. The combination of active ingredients comprises at least a SERCA inhibitor and at least a Calmodulin antagonist.
Inhibition of Thymine DNA Glycosylase in the Treatment of Cancer
申请人:Institute for Cancer Research d/b/a/ The Research Institute of Fox Chase Cancer Center
公开号:US20160199381A1
公开(公告)日:2016-07-14
The invention provides compositions, kits, and methods for inducing growth arrest, differentiation, or senescence of cancer cells that express thymine DNA glycosylase, and treating the cancer accordingly. The methods comprise inhibiting expression or biologic activity of thymine DNA glycosylase in cancer cells. Inhibition of thymine DNA glycosylase in cancer cells may induce the cells to revert to a healthy, non-cancerous phenotype and/or may induce the cells to senesce. Cancer cells include melanoma, lung, prostate, pancreatic, ovarian, brain, colon, recto-sigmoid colon, and breast cancer cells.